scispace - formally typeset
X

Xupeng Yang

Researcher at Shanghai Jiao Tong University

Publications -  8
Citations -  109

Xupeng Yang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Chemistry & Cancer research. The author has an hindex of 3, co-authored 5 publications receiving 16 citations.

Papers
More filters
Journal ArticleDOI

Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance.

TL;DR: NPs-cRGD with ultrasound promoted the apoptosis of resistant ovarian cancer cells by multiple mechanisms, including increased cellular drug accumulation, reversed antiapoptotic effects by siBIRC5, and enhanced ROS levels.
Journal ArticleDOI

Nano-ultrasonic Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism Reprogramming and Tumor Autophagy.

TL;DR: The tumor microenvironment-responsive nano-ultrasonic contrast agent Pt(IV)/CQ/PFH NPs-DPPA-1 boosts the ratio of mature dendritic cells (mDCs) and proinflammatory macrophages by reprogramming the metabolism of immature DCs and tumor-associated macrophage (TAMs) by reducing platinum(IV) in cancer cells or iDCs to cisplatin.
Journal ArticleDOI

Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.

TL;DR: In this paper, a novel tumor-targeted nanosized ultrasound contrast nanobble loaded with chlorin e6 (Ce6), metformin (MET), and perfluorohexane (PFH) was fabricated.
Journal ArticleDOI

Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell-Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer

TL;DR: In this paper, the authors developed prostatespecific membrane antigen aptamer (Apt)-functionalized shell-core nanoparticles (PTX/siRNAs NPs-Apt) to overcome PTX-resistant LNCaP/PTX cells.
Journal ArticleDOI

Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation

TL;DR: In this article, the authors reported the first inhibitor of DR6/APP interaction as a novel class of anti-hematogenous metastatic agent, which is obtained by rationally utilizing three combined strategies including selection based on phage display library, d-retro-inverso modification, and multiple conjugation of screened peptidomimetic with 4-arm PEG.